September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Abdul Mannan: DOACs in Cancer-Associated VTE – When to Avoid Them, And When LMWH Wins

Abdul Mannan/LinkedIn

Jun 27, 2026, 14:01

Abdul Mannan: DOACs in Cancer-Associated VTE – When to Avoid Them, And When LMWH Wins

Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:

“‘A DOAC is the right answer for cancer clots, until it suddenly isn’t. Here are the lines you don’t cross.’

DOACs have quietly become first-line for many cancer-associated clots. But reach for one in the wrong patient and you can cause the bleed you were trying to prevent.

NCCN 2026 splits the cautions into two groups. Worth knowing both cold.

Absolute, pick another drug:

Antiphospholipid syndrome, especially triple-positive. Warfarin still wins here.
Pregnancy or breastfeeding.
CrCl under 30 mL/min.
Child-Pugh B/C liver disease.
Strong dual CYP3A4 and P-gp interactions.

Relative, prefer LMWH:

Luminal GI or gastro-oesophageal lesions. Edoxaban and rivaroxaban raised GI bleeding in Hokusai VTE Cancer and SELECT-D. Apixaban looked kinder on the gut in CARAVAGGIO.
Genitourinary tract lesions or recent instrumentation.
Platelets under 50.
Poor gut absorption, or vomiting, which hits up to half of cancer patients.
Primary brain tumours or untreated brain metastases.

The pattern is simple. If the drug cannot be absorbed, cleared, or kept away from a raw mucosal surface, the oral route stops being the clever choice.

Which of these trips people up most on your wards?”

Abdul Mannan: DOACs in Cancer-Associated VTE - When to Avoid Them, And When LMWH Wins